Malin Life Sciences Holdings Ltd 3
3 · Poseida Therapeutics, Inc. · Filed Jul 9, 2020
Insider Transaction Report
Form 3
Malin Life Sciences Holdings Ltd
10% Owner
Holdings
Series A Convertible Preferred Stock
→ Common Stock (7,013,918 underlying)Series A-1 Convertible Preferred Stock
→ Common Stock (1,168,985 underlying)Series B Convertible Preferred Stock
→ Common Stock (690,124 underlying)Series C Convertible Preferred Stock
→ Common Stock (315,098 underlying)
Footnotes (2)
- [F1]All shares of preferred stock, $0.0001 par value per share, of the Issuer, (i) are reflective of a 1-for-1.247 reverse stock split on the Issuer's common stock, $0.0001 par value per share ("Common Stock"), which became effective on July 2, 2020, (ii) have no expiration date and (iii) will automatically convert into the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering.
- [F2]Malin Life Sciences Holdings Ltd, the record holder of the shares, is a wholly owned subsidiary of Malin Corporation plc. Malin Corporation plc may be deemed to beneficially own the shares and may be deemed to share voting and dispositive power over these shares.